FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
about
Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasisThe 2011 IASLC/ATS/ERS pulmonary adenocarcinoma classification: a landmark in personalized medicine for lung cancer managementDelivery of RNAi Therapeutics to the Airways-From Bench to BedsideInternational association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinomaEvolving Therapies and FAK Inhibitors for the Treatment of CancerOut of the shadows: CXC chemokines in promoting aberrant lung cancer angiogenesisOpportunities and challenges for successful use of bevacizumab in pediatrics.Theragnostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsionsEvaluation of the effect of transcytolemmal water exchange analysis for therapeutic response assessment using DCE-MRI: a comparison studyA cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer.C4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinomaAddition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression.A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessmentAntiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer.Angiogenesis inhibitors in the treatment of non-small cell lung cancerClassification of non-small cell lung cancer based on copy number alterationsVEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancerFrom the bench to bedside: biological and methodology considerations for the future of companion diagnostics in nonsmall cell lung cancer.Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis.Involvement of Flt-1 (VEGF receptor-1) in cancer and preeclampsia.The high diagnostic accuracy of combined test of thyroid transcription factor 1 and Napsin A to distinguish between lung adenocarcinoma and squamous cell carcinoma: a meta-analysis.Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis.Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC)Bevacizumab in the treatment of metastatic breast cancer: friend or foe?Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer.Bevacizumab for the treatment of nonsquamous non-small-cell lung cancer in Portugal: a retrospective, multicenter studyHow Do Payers Respond to Regulatory Actions? The Case of BevacizumabLong-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab.Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classificationPharmacokinetics, lymph node uptake, and mechanistic PK model of near-infrared dye-labeled bevacizumab after IV and SC administration in mice.Reevaluation and reclassification of resected lung carcinomas originally diagnosed as squamous cell carcinoma using immunohistochemical analysisUse of Bevacizumab in Community Settings: Toxicity Profile and Risk of Hospitalization in Patients With Advanced Non-Small-Cell Lung CancerCarboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer.The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops.A retrospective analysis of cisplatin, pemetrexed, and bevacizumab in previously treated non-small-cell lung cancerDynamic fractal signature dissimilarity analysis for therapeutic response assessment using dynamic contrast-enhanced MRI.Bevacizumab as first-line therapy in advanced non-small-cell lung cancer: a brazilian center experience.Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy.Beyond anti-VEGF: dual-targeting antiangiogenic and antiproliferative therapy.
P2860
Q22305863-68644C32-6127-4164-98FD-32250C5B1F2AQ26851443-E6635BFA-C3F4-4D66-8379-0D4411E9847CQ28067306-7C35C71F-5FBA-4E96-9615-1DF98C84DA4CQ28303718-1DF698F7-18CC-40EC-8876-AA1042A39903Q28972291-3C15F8B2-C977-4EF0-9B52-080E573DA869Q30438282-FF3D865F-6B8D-4B3C-9190-0B19FC400073Q30454883-ED814520-8B16-4E16-81CA-423B0B3949DCQ30474759-BE8807F6-4137-440D-9C24-170DDB1E1D78Q31106171-F328DCA4-C937-4F0B-9C45-161D06CEC1C6Q34029999-CA8B3898-D73C-4205-8732-FCDD48887128Q34031219-33E185DF-8793-47C0-A2BF-79ADEBD19016Q34538361-5810C399-B966-4E89-B470-CB58DE784B2BQ34765364-C84000A3-3338-408D-B9F7-206E0CE3FE38Q34854658-684C0BC8-1144-4AD8-B910-48717C169C22Q35076198-6476945C-F89B-40C1-99B3-C962054E1AE8Q35088670-9F6641CF-E0D9-4EDD-8F65-A9C4C10D496AQ35112894-99997FE7-F5D9-4B7A-AF63-64988E9B5081Q35117568-4D27BF29-45C9-4972-99CF-86587740C7D1Q35144007-CCC4E68D-7E1F-497F-BF3C-03471A8A2D36Q35145097-92BC1C4B-DAD1-410D-AF1A-4B28E5654CDBQ35202946-8A4F9B8D-64F9-4260-BF7E-34B2A963F436Q35545472-F660F477-8C4E-48DC-B0DD-5FCF98FB77F1Q35563524-2A027924-101B-4CAD-AD79-31BC6AC08194Q35583816-B5DC1528-B456-4234-A0DB-D977675B36F0Q35696743-2660086F-59D1-4982-81F9-3A7AF9276A32Q35813229-7F8EFA28-48A9-40DD-9434-53108C3D0A7BQ35841620-48BAE2BC-3193-43B7-92E6-055C0B691AFFQ35866147-87DC5FAD-7BB1-411E-A027-17BA48F5A6AEQ35872579-9E810503-8F98-44C5-B0C3-1614A618CE03Q35875227-EF30CED8-6A1D-487F-BD1A-ECEA9AC23DAAQ35888386-333CF298-0D6A-42F7-A4DC-D5B0F682E578Q35957585-2B67AA9B-C3B7-4E85-9A3E-B339C0CECB92Q36073707-13EA1B83-894E-4709-9695-E52A1265F6CAQ36163935-9405DF0F-12F2-4DDA-8AC0-5F2887032FACQ36172732-023E9DC8-B903-4F68-9EE8-E2FD12DB9274Q36356058-87734A2F-A8F1-4AE6-B47E-D9EC35056B07Q36599503-54345D4D-8FD1-43C2-A22C-631B984025D4Q36649162-B8DEC66F-9CE0-4B02-8116-5C0179F23F64Q36661727-87E4A886-571F-4041-AD62-9F1B3829C98BQ36881812-FB0A9301-5866-4FE4-B33E-79888CF62C67
P2860
FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
FDA drug approval summary: bev ...... us non-small cell lung cancer.
@ast
FDA drug approval summary: bev ...... us non-small cell lung cancer.
@en
type
label
FDA drug approval summary: bev ...... us non-small cell lung cancer.
@ast
FDA drug approval summary: bev ...... us non-small cell lung cancer.
@en
prefLabel
FDA drug approval summary: bev ...... us non-small cell lung cancer.
@ast
FDA drug approval summary: bev ...... us non-small cell lung cancer.
@en
P2093
P1433
P1476
FDA drug approval summary: bev ...... us non-small cell lung cancer.
@en
P2093
Joe Gootenberg
Martin H Cohen
Patricia Keegan
Richard Pazdur
P304
P356
10.1634/THEONCOLOGIST.12-6-713
P577
2007-06-01T00:00:00Z